Compare AVAH & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | ANAB |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2015 |
| Metric | AVAH | ANAB |
|---|---|---|
| Price | $8.52 | $60.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $9.75 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.8M | 497.3K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | 91.02 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $2,433,199,000.00 | $234,603,000.00 |
| Revenue This Year | $7.31 | N/A |
| Revenue Next Year | $5.59 | $52.14 |
| P/E Ratio | $44.58 | ★ N/A |
| Revenue Growth | 20.19 | ★ 157.01 |
| 52 Week Low | $3.73 | $17.11 |
| 52 Week High | $10.32 | $73.30 |
| Indicator | AVAH | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 76.83 | 56.98 |
| Support Level | $7.77 | $52.32 |
| Resistance Level | $8.68 | $67.69 |
| Average True Range (ATR) | 0.30 | 2.96 |
| MACD | 0.16 | 0.96 |
| Stochastic Oscillator | 94.71 | 83.52 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).